Expedition Therapeutics: Valuation, Funding & Investors
Expedition Therapeutics is a biotechnology company focused on developing innovative therapies for serious inflammatory and respiratory diseases. Their lead program, EXPD-101, is a next-generation DPP1 inhibitor with the potential to be a first-in-class treatment for chronic obstructive pulmonary disease (COPD) and other neutrophil-driven diseases. The company leverages deep expertise in translational science and clinical development, aiming to improve patient outcomes through cutting-edge therapeutic solutions.
Leadership & Board
- Current Number of Employees
- 18
- Current LinkedIn Followers
- 4,149
Latest Estimated Valuation
- Total Amount Raised
- $280M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $115M
- Latest Funding Round
- Series B
Employee Trend
Expedition Therapeutics had 18 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Expedition Therapeutics had 4,149 followers as of November 9, 2026. The number of followers increased by 54 (1.32%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 05, 2026 | Series B | $115.00M | ― |
| Oct 09, 2025 | Series A | $165.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Forbion | Series A |
| Novo Holdings | Series A |
| Logos Capital | Series A |
| Venrock Healthcare Capital Partners | Series A |
| Dawn Biopharma | Series A |
| Sanofi Ventures | Series A |
| Sofinnova Investments | Series A |
| Adage | Series A |
Similar Companies
A snapshot of private companies similar to Expedition Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
